Table 3.
Type and dose of outpatient initiation of β-blockers, stratified by LVEF
| β-Blocker Initiated |
LVSD (n = 362) |
No LVSD (n = 283) |
||
|---|---|---|---|---|
| N | Dose, mg/24 hr Median (IQR) | N | Dose, mg/24 hr Median (IQR) | |
| Atenolol |
12 |
25 (12.5-25) |
56 |
25 (25–25) |
| Carvedilol |
63 |
12.5 (6.25-25) |
12 |
9.375 (6.25-18.75) |
| Metoprolol Succinate |
124 |
25 (12.5-37.5) |
42 |
12.5 (12.5-25) |
| Metoprolol Tartrate |
163 |
50 (25–50) |
173 |
50 (25–50) |
| Hospitalization in next 30 days following β-blocker initiation (unadjusted) | 6 (0.93%) | 9 (1.40%) | ||
LVSD = left ventricular systolic dysfunction (LVEF ≤40% or moderate/severe LV systolic dysfunction). The 6 patients initiated on a β-blocker other than those listed were excluded.